Prostatic Fluid Cells
Abstract
Most research that requires long-term propagation of prostate cancer (PCA) cells is carried out with three cell lines: DU 145, PC-3, and LNCaP. All but one of these lines, LNCaP, fail to express prostate specific antigen (PSA), androgen receptors, and/or any other prostate phenotype. Some prostatic fluids contain PCA cells. Our goals were (1) to test the tumorigenicity of and to develop transplantable xenografts from POA cells in prostatic fluid, (2) to develop methods for enhancing the tumorigenicity of small numbers of these PCA cells without deliberately altering their genes, (3) to test these methods for enhancement of tumorigenicity with prostatic fluid cells, and (4) to initiate clinical follow-up. As detailed in the body of our report, our aims that required prostatic fluid have been limited by exceptionally weak clinical collaboration that has become progressively weaker. The fluids that we tested earlier were%promising. The quantity and quality of prostatic fluids received from our clinical Collaborator, Dr. Martin Resnick, declined progressively. Coinjection of lethally irradiated, growth-factor-producing cells was encouraging in some experiments in the case of some tumors; however, results were quite variable in repeated experiments.
Document Details
- Document Type
- Technical Report
- Publication Date
- May 01, 2005
- Accession Number
- ADA439716
Entities
People
- Thomas G. Pretlow
Organizations
- Case Western Reserve University